These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36879149)

  • 61. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].
    Zhu MY; Zhu Y; Chen RR; Zhu LX; Zhu JJ; Li XY; Zhou D; Yang XD; Zheng YL; Xie MX; Sun JN; Huang XB; Li L; Xie WZ; Ye XJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):100-105. PubMed ID: 32135624
    [No Abstract]   [Full Text] [Related]  

  • 62. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
    Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
    Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
    Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
    Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clonal Evolution of Acute Myeloid Leukemia with
    Li Y; Su L
    Turk J Haematol; 2019 May; 36(2):128-130. PubMed ID: 30201598
    [No Abstract]   [Full Text] [Related]  

  • 65. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.
    Hou HA; Lin LI; Chen CY; Tien HF
    Br J Cancer; 2009 Aug; 101(4):738-40. PubMed ID: 19623175
    [No Abstract]   [Full Text] [Related]  

  • 66. HoxA9 binds and represses the Cebpa +8 kb enhancer.
    Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
    PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Familial myelodysplasia and acute myeloid leukaemia--a review.
    Owen C; Barnett M; Fitzgibbon J
    Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
    Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification and lineage restriction analyses of preleukemia cells in a sporadic biallelic CEBPA mutated acute myeloid leukemia patient.
    Chen Y; Liu Q; Shi Z; Zhang G; Wang M; Mi Y; Wei H; Wang J
    Int J Lab Hematol; 2021 Jun; 43(3):e145-e147. PubMed ID: 33369101
    [No Abstract]   [Full Text] [Related]  

  • 70. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
    Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
    Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
    Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
    Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Ng CWS; Kosmo B; Lee PL; Lee CK; Guo J; Chen Z; Chiu L; Lee HK; Ho S; Zhou J; Lin M; Tan KML; Ban KHK; Tan TW; Chng WJ; Yan B
    J Clin Pathol; 2018 Jun; 71(6):522-531. PubMed ID: 29180507
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
    Taube F; Georgi JA; Kramer M; Stasik S; Middeke JM; Röllig C; Krug U; Krämer A; Scholl S; Hochhaus A; Brümmendorf TH; Naumann R; Petzold A; Mulet-Lazaro R; Valk PJM; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Herold S; Stölzel F; Sockel K; von Bonin M; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
    Blood; 2022 Jan; 139(1):87-103. PubMed ID: 34320176
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications.
    Zhang F; Shen Z; Xie J; Zhang J; Wu Q; Jiang R; Zhao X; Yang X; Chen S
    Blood Cancer J; 2024 Apr; 14(1):59. PubMed ID: 38594276
    [No Abstract]   [Full Text] [Related]  

  • 77. Characteristic immunophenotype and gene co-mutational status orchestrate to optimize the prognosis of CEBPA mutant acute myeloid leukemia.
    Chen X; Abuduaini D; Zhang Y; Long J; Lin X; Zhu H; Li J; Shen Y
    Blood Cancer J; 2023 May; 13(1):70. PubMed ID: 37147303
    [No Abstract]   [Full Text] [Related]  

  • 78. CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.
    Hughes JM; Salvatori B; Giorgi FM; Bozzoni I; Fatica A
    J Hematol Oncol; 2014 Sep; 7():69. PubMed ID: 25252716
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.
    Renneville A; Boissel N; Gachard N; Naguib D; Bastard C; de Botton S; Nibourel O; Pautas C; Reman O; Thomas X; Gardin C; Terré C; Castaigne S; Preudhomme C; Dombret H
    Blood; 2009 May; 113(21):5090-3. PubMed ID: 19289855
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
    Liao XY; Fang JP; Zhou DH; Qiu KY
    Hematol Oncol; 2022 Apr; 40(2):258-268. PubMed ID: 34816468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.